ENBREL Drug Profile

Summary for Tradename: ENBREL

High Confidence Patents:	13
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for ENBREL
Recent Clinical Trials:	See clinical trials for ENBREL

See drug prices for ENBREL

Recent Clinical Trials for ENBREL

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
mAbxience Research S.L.	PHASE3
mAbxience Research S.L.	PHASE1
Benaroya Research Institute	Early Phase 1

See all ENBREL clinical trials

Pharmacology for ENBREL

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ENBREL Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ENBREL Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,307,483	2038-04-20	DrugPatentWatch analysis and company disclosures
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11,491,223	2038-09-27	DrugPatentWatch analysis and company disclosures
Immunex Corporation	ENBREL	etanercept	For Injection	103795	5,395,760	2010-05-10	DrugPatentWatch analysis and company disclosures
Immunex Corporation	ENBREL	etanercept	For Injection	103795	5,605,690	2015-02-08	DrugPatentWatch analysis and company disclosures
Immunex Corporation	ENBREL	etanercept	For Injection	103795	5,712,155	2014-11-29	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ENBREL Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,010,585	2035-06-16	Patent claims search
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,016,338	2036-12-20	Patent claims search
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,028,940	2037-03-16	Patent claims search
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,047,141	2035-01-29	Patent claims search
Immunex Corporation	ENBREL	etanercept	For Injection	103795	10,058,589	2033-10-24	Patent claims search

International Patents for ENBREL

Country	Patent Number	Estimated Expiration
South Korea	102413592
Japan	2721745
Australia	4920993
Greece	3019333
Japan	H07504203

Supplementary Protection Certificates for ENBREL

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
132000900852970	Italy
15/2000	Austria		PRODUCT NAME: ETANERCEPT; NAT. REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: LI 55365 20000201
C300129	Netherlands		PRODUCT NAME: ETANERCEPTUM; NATL. REGISTRATION NO/DATE: EU/1/99/126/001 20000203; FIRST REGISTRATION: CH 55365 20000201
SPC/GB03/027	United Kingdom		PRODUCT NAME: RECOMBINANT TNF-R P75 IGG FUSION PROTEIN LACKING THE FIRST CONSTANT REGION OF THE HEAVY CHAIN OF HUMAN IGG, SUCH AS ETANERCEPT; REGISTERED: CH SWISS 55365 20000201; UK EU/1/99/126/001 20000203; UK EU/1/99/126/002 20000203
SZ 18/2003	Austria		PRODUCT NAME: ETANERCEPT

Market Dynamics and Financial Trajectory for Enbrel (Etanercept)

Last updated: February 19, 2026

What is the current market position of Enbrel?

Enbrel (etanercept), a biologic TNF inhibitor developed by Amgen in collaboration with Pfizer, holds a significant share in the biologic rheumatoid arthritis (RA) market. Since its FDA approval in 1998, it has become a leading therapy for autoimmune diseases, including RA, psoriasis, ankylosing spondylitis, psoriatic arthritis, and juvenile idiopathic arthritis.

As of 2022, Enbrel's global sales totaled approximately $4.5 billion, representing a decline from peak sales of over $6 billion in 2014. The decline stems from increased biosimilar competition, especially in Europe and Asia, and the expiration of patents in multiple regions.

How does Enbrel compare to key competitors?

Product	Company	Approval Year	Patent Expiry	Estimated 2022 Sales	Indications
Enbrel	Amgen/Pfizer	1998	2018 (EU), 2028 (US)	$4.5 billion	RA, psoriasis, psoriatic arthritis, ankylosing spondylitis
Humira (adalimumab)	AbbVie	2002	2012 (EU), 2034 (US)	$20 billion (2022 global)	RA, Crohn’s, UC, psoriasis
Simponi (golimumab)	Janssen	2009	2022 in US	$1.2 billion	RA, psoriatic arthritis, UC

Biosimilars of Enbrel launched in Europe and parts of Asia in 2018-2020 led to price reductions of up to 30%, impacting revenue streams.

What are the key factors influencing Enbrel's market dynamics?

Patent and biosimilar landscape

Patent expirations in US and EU opened the market for biosimilars, causing downward pricing pressure. Biosimilars now account for approximately 25-30% of Enbrel's global volume.

Regulatory environment

Approval pathways for biosimilars in the US (via FDA's 351(k) pathway) facilitate market entry. The FDA approved the Enbrel biosimilar, Erelzi (etanercept-szzs), in 2016. European regulators approved multiple biosimilars starting in 2018.

Pricing strategies

Amgen and Pfizer reduced list prices by roughly 25-30% upon biosimilar entry. Discounting strategies, such as rebates and formulary positioning, are critical for maintaining market share amid generic competition.

Market expansion

Enbrel's presence in emerging markets, especially China and India, continues to grow, driven by demand for biologics and improved healthcare access. Local biosimilars further dilute Enbrel's market share.

Innovation and pipeline

Amgen's pipeline includes next-generation TNF inhibitors and biosimilar versions. However, no substantial new indications or enhancements for Enbrel have been announced recently, limiting growth prospects.

What is the financial outlook for Enbrel?

Revenue projections

Forecasts indicate a continued decline in Enbrel's sales driven by biosimilar competition, with estimates projecting revenue dropping to approximately $2.5 billion by 2025. The US market's impact remains muted due to patent protections until 2028.

Cost pressures and profitability

Manufacturing costs for biologics like Enbrel are relatively stable, but pricing pressures and discounts reduce profit margins. Amgen's gross margin for Enbrel was approximately 75% in 2022, down from 80% in 2015.

Strategic shifts

Amgen relies on biosimilar portfolio expansion, including biosimilar versions of other TNF inhibitors and autoimmune therapeutics, to offset declining Enbrel revenue.

What are the regulatory and legal risks?

Patent litigations in the US and EU persist until 2028, delaying biosimilar market entry. Legal challenges remain from patent holders seeking extensions or asserting new patents. Regulatory agencies are increasingly scrutinizing biosimilar approvals, affecting timelines.

How does market access and payer coverage influence Enbrel's financials?

Limited reimbursement for biosimilars in certain regions constrains price competition. Payer negotiations favor biosimilars, but brand loyalty and physician prescribing habits sustain Enbrel's sales in the US and Europe. Contractual rebates and prior authorization procedures influence access and revenue.

Summary of Key Market Drivers

• Patent expirations and biosimilar entries reduce revenue.
• Cost-cutting and strategic negotiations mitigate volume and pricing declines.
• Market growth in emerging regions sustains revenue streams.
• Pipeline developments are limited, with minimal new indications.
• Regulatory and legal frameworks shape competitive entry timelines.

Key Takeaways

• Enbrel remains a commercial leader in autoimmune biologics, but its dominance diminishes due to biosimilar competition.
• Revenue is projected to decline at a compound annual growth rate (CAGR) of approximately -10% from 2022 to 2025.
• Patent protection in the US extends until 2028, after which biosimilar penetrance will accelerate.
• Amgen shifts focus toward biosimilar portfolio expansion and pipeline diversification.
• Market momentum is driven by geographic expansion and payer strategies.

FAQs

1. When will Enbrel's patents expire in key markets?
In the US, patent protections expire in 2028. European patent expirations occurred in 2018, leading to biosimilar competition.

2. How have biosimilars affected Enbrel's sales?
Biosimilars have caused a 25-30% reduction in list prices and a significant volume increase, leading to overall sales decline since 2018.

3. What are the main competing products?
Humira, Simponi, and Remicade are key rivals in the TNF inhibitor segment, with Humira leading globally.

4. Is there pipeline innovation specific to Enbrel?
No publicly announced next-generation versions or indications for Enbrel are currently in advanced development.

5. How does market penetration vary across regions?
Enbrel faces steep biosimilar competition in Europe and Asia, while US sales benefit from patent protection until 2028 with gradual biosimilar penetration.

References

[1] Amgen. (2022). Form 10-K. Retrieved from https://www.amgen.com
[2] FDA. (2016). Approval of Erelzi (etanercept-szzs). Food and Drug Administration.
[3] IQVIA. (2022). Biotech and biosimilar market report.
[4] European Medicines Agency. (2022). Biosimilar approvals.
[5] Pfizer. (2023). Biologic pipeline updates.